MedTrace Logo

Pharmacological Enhancement of Glymphatic Function in Humans

NCT07432997 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-02-25

No results posted yet for this study

Summary

Alzheimer's disease is linked in part to the buildup of harmful proteins in the brain, including amyloid and tau. Most current treatments aim to remove these proteins directly. This study explores a different approach: helping the brain clear waste more effectively during sleep. The investigators will test whether certain medications can safely boost the brain's natural "cleaning system," known as the glymphatic system, in healthy older adults. Participants will receive controlled sleep treatments and blood tests to measure protein clearance. If successful, this strategy could support new therapies that work alongside existing Alzheimer's treatments.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Dexmedetomidine

Treatment

DRUG

Dexmedetomidine and Midodrine

Treatment

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Stanford University

    collaborator OTHER

  • Washington State University

    collaborator OTHER

  • Applied Cognition

    lead INDUSTRY

Principal Investigators

  • Paul Dagum, MD PhD · Applied Cognition

  • Albert Cheung, MD · Stanford Hospital

  • Brieann C Satterfield, PhD · Washington State University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-11
Primary Completion
2024-09-13
Completion
2024-09-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07432997 on ClinicalTrials.gov